Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132014 | 1.00 | SLC5A1 (0.37) | SLC5A1CNR1CNR2EPHX2CRACR2A | |
| SCHEMBL1131660 | 0.86 | MDM2 (0.45) | CRACR2A | |
| SCHEMBL1131253 | 0.79 | SLC5A1 (0.38) | SLC5A1CNR1CNR2EPHX2CRACR2A | |
| SCHEMBL1131260 | 0.76 | SLC5A1 (0.39) | SLC5A1EPHX2CRACR2AMIF | |
| SCHEMBL1132019 | 0.74 | PTGS2 (0.40) | MGLLFAAH | |
| SCHEMBL1132021 | 0.74 | PTGS2 (0.40) | MGLLFAAH | |
| SCHEMBL1132013 | 0.71 | MEN1 (0.37) | SLC5A1EPHX2FAAH | |
| SCHEMBL1132015 | 0.71 | MEN1 (0.37) | SLC5A1EPHX2FAAH | |
| SCHEMBL3889862 | 0.71 | SLC5A1 (0.40) | SLC5A1EPHX2CRACR2AMIF | |
| SCHEMBL3889857 | 0.71 | SLC5A1 (0.40) | SLC5A1EPHX2CRACR2AMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |